). Neutrophil recovery occurred on day +10 and was associated with GVHD grade III of the skin which was treated with cyclosporin A (CsA) and prednisone. Because of fever of unknown origin and progressive fatigue combined with hypotension on day +15 after second PBSCT, echocardiography was performed which revealed a dramatic decrease in systolic function compared to the status pre-transplant. On the same day acute heart failure with consecutive ventricular fibrillation occurred. Although resuscitation was performed immediately the patient died. The autopsy revealed massive infiltration by donor CD8-positive lymphocytes with concomitant extensive damage of the heart tissue. Acute myocarditis of viral origin was excluded by in situ hybridization and nested PCR techniques. In this patient, myocardial involvement by acute GVHD seems to have triggered a fatal arrhythmia and heart failure. Bone Marrow Transplantation (2001) 27, 107-109. Keywords: GVHD; heart; HHV-6
with a procedure-related mortality of up to 50% in the first 100 days after BMT. Remission induction can be achieved by omitting GVHD prophylaxis, thus maximizing GVL effects. Nevertheless, GVHD remains one of the persistent problems of allogeneic blood stem cell transplantation mostly affecting the skin, gut and the liver. To our knowledge, there is only one report in the literature suggesting an acute GVHD of the heart with reversible complete heart block. 1 We report a case of allogeneic unrelated PBSC transplantation in a patient with AML which relapsed early after first transplant. Acute GVHD occurred and the patient died due to acute heart failure on day +15 after a second PBSCT. Histological and immunohistochemical investigations of the heart provided evidence of irreversible heart damage caused by massive infiltration by CD8-positive lymphocytes, thus suggesting acute GVHD of the heart.
Case report
A 17-year-old male with AML FAB M4 (46 XY) diagnosed 1 year previously was admitted to our hospital. Initial treatment had included two cycles of idarubicine 12 mg/m 2 once daily i.v. for 3 days (total dose 72 mg/m 2 ) plus Ara-C 1000 mg/m 2 by continuous infusion on 6 consecutive days (total dose 12 g/m Two months later an allogeneic peripheral blood stem cell transplant from an HLA-identical unrelated donor was performed. Echocardiography pre-transplant showed an ejection fraction of more than 60% and normal cardiac parameters. Both donor and host were CMV-negative and CMV-negative blood products were given. The first conditioning regimen consisted of busulfan (total dose 13.2 mg/kg), etoposide (total dose 30 mg/kg), cyclophosphamide
Bone Marrow Transplantation (total dose 120 mg/kg) and ATG (total dose 10 mg/kg). The patients received T cell-depleted PBSCs containing 6.2 ϫ 10 6 /kg CD34-positive-cells. His course after transplantation was uneventful and CsA was stopped on day +100 after PBSCT.
On day +120 the patient again presented with relapsing disease and decreasing donor chimerism. A second transplant was performed using unmanipulated PBSC from the same donor. At the time of the second transplant the patient's Karnofsky score had been 90%. Cytoreductive therapy was performed with mitoxantrone 7 mg/m 2 /day i.v. ). An unmanipulated PBSC harvest of the HLA-identical unrelated donor was transfused containing 6 ϫ 10 6 CD34-positive stem cells and 2 ϫ 10 8 CD3-positive T cells/kg, respectively. No GVHD prophylaxis was used. Starting on day +1 GM-CSF at a dose of 60 g/m 2 per day was administered i.v. for a period of 12 days.
Methods

Mobilization and harvest of peripheral blood stem cells
The donor received 7.5 g/kg of granulocyte colony-stimulating factor subcutaneously per day for 5 consecutive days. Two large volume aphereses were performed on days 5 and 6 using a continuous flow cell separator (Cobe Spectra, Lakewood, CO, USA).
Chimerism analysis by PCR
Donor chimerism was assessed using a quantitative multiplex PCR assay with amplification of nine tetranucleotide repeats and the amelogenin locus as described. 2 Hematological recovery was defined as time to reach a sustained absolute neutrophil count (ANC) Ͼ0.5 ϫ 10 9 /l and a platelet count Ͼ20 ϫ 10 9 /l. Acute GVHD was graded following published criteria. 3 
PCR and in situ hybridization of the heart
Myocardial infection by cardiotropic agents, such as enteroviruses (EV), parvovirus B19 (PVB19), adenoviruses (ADV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), herpes simplex virus 1 and 2 (HSV-1 and -2), human herpesvirus 6 (HHV6), Chlamydia pneumoniae or Borrelia burgdorferi was investigated by nested (RT)-polymerase chain reaction. [4] [5] [6] Additionally, viral infection of the heart by EV and PVB19 was excluded by means of radioactive in situ hybridization. 4, 7 Immunohistochemical studies For immunohistochemical characterization of inflammatory cells in the myocardium, 4-m dewaxed paraffin-embedded tissue sections were tested by an avidin-biotin immunoperoxidase method according to the manufacturer's protocol (Vectastain Elite ABC Kit, Vector, Burlingame, CA, USA) applying the following monoclonal antibodies, CD3 (T cells, Novocastra Laboratories, Newcastle upon Tyne, UK), CD8 (Dako, Glostrup, Denmark), CD68 (Dako). Controls with normal mouse serum were performed to exclude nonspecific staining. As a substrate for peroxidase, 3.3Ј-diaminobenzidine tetrahydrochloride was used.
Results
On day +7 fever combined with an acute GVHD grade III of the skin occurred. Treatment with 2 mg/kg cyclosporin A (CsA) twice daily i.v. and 1.5 mg/kg/day prednisone was started with good response. Chimerism improved rapidly reaching 100% on day +10 after transplantation. Although GVHD of the skin improved, an increase in liver enzymes (aspartate amino-transferase max. 5.9 mol/l; normal range 0.1-0.62 mol/l, alanine aminotransferase max. 9.5 mol/l; normal range 0.1-0.67 mol/l), bilirubin (274.6 mol/l, normal range 1.0-16.0 mol/l) and diarrhea, compatible with clinical GVHD, occurred suggesting an exacerbation of the GVHD. At the same time, the patient showed signs of low-output syndrome associated with progressive fatigue, orthostatic failure and hypotension. Because of this and recurrent, treatment-resistant fever, echocardiography of the heart was performed on day +15 revealing global dysfunction with an ejection fraction less than 30% and a small pericardial effusion (7-12 mm) not compromising heart function. ECG demonstrated a sinus tachycardia with a low voltage over all leads without signs of cardiac ischemia. Fever was accompanied by a rising LDH up to 28.27 mol/l (normal range 3.8-7.7 mol/l) on day +15 after PBSCT. On the same day, the patient suffered acute ventricular fibrillation and cardiopulmonary resuscitation was started immediately. In the meantime the ECG showed signs of an electromechanical decoupling. Echocardiography showed a global akinesia and resuscitation was stopped after 2 h because of failure to establish adequate cardiac output. Permission for autopsy was obtained for the heart only which revealed severe damage with cytolysis ( Figure  1b) and massive infiltration by CD3-positive T cells (Figure  1c) , most of which were CD8-positive cytotoxic T cells (Figure 1d) . Additionally, a small number of CD68-positive macrophages (Figure 1e) were detected. Chimerism analysis of the specimen revealed that more than 70% of all nucleated cells in the myocardial biopsy were of donor origin (Figure 1a) . For this reason, we conclude that most of the CD8-positive cells infiltrating the myocardium were derived from the donor. In situ hybridization and nested PCR of the myocardial tissue were negative for EV, ADV, HCMV, EBV, HSV-1 and -2, PVB19, Chlamydia pneumoniae and Borrelia burgdorferi. Only low levels of HHV6-specific nucleic acid sequences were detected.
Discussion
In the case reported, severe GVHD occurring after the second PBSCT was a result of omitting immunosuppressive prophylaxis to enhance a graft-versus-leukemia (GVL) effect. GVHD induction was accompanied by severe heart failure with massive myocardial infiltration by donorderived CD8-positive cells. Only very low levels of HHV-6 were detected which are not likely to be responsible for this reaction. In addition to the known sites affected by acute GVHD myocardial involvement occurred in this patient. To our knowledge, there is only one case reported of reversible complete heart block occurring during acute GVHD. 1 The patient had not shown any clinical signs of heart failure before conditioning for the second transplant was started. Therefore, echocardiography was not repeated. Nevertheless, the first diagnosis which should be considered is myocardial damage due to anthracycline-containing chemotherapy which can lead either to early cardiac damage or to late-onset cardiotoxicity years after receiving chemotherapy. 8 The cumulative dose of mitoxantrone and idarubicine given to the patient is equivalent to 500 mg/m 2 daunorubicin. Although this dose should be tolerated by a younger patient without an increased risk for cardiac events, we cannot rule out that anthracycline pretreatment contributed significantly to the cardiotoxicity. Conventional diagnostic methods such as echography are not sufficiently sensitive for the detection of early cardiac impairment. Myocardial damage may have resulted in an upregulation of HLA class I and costimulatory molecules which are normally not expressed in cardiac tissue. 9 Consecutively, CD8-positive T cells might have been activated by antigenpresenting cells inducing a cytotoxic effect against cardiomyocytes. GM-CSF use could have played an underestimated role in our patient. This cytokine was used after cytoreductive therapy instead of G-CSF because it has been shown to promote effects including the generation of disease-specific dendritic cells and enhancement of GVHDrelated cytokines which might be useful for adoptive immunotherapy. Acute heart failure was caused by a massive infiltration of CD8-positive cells in this patient. AtypiBone Marrow Transplantation cal manifestations and sites of GVHD have to be taken into account in patients with high risk leukemia who receive no standard GVHD prophylaxis after transplantation.
